journal article·2016

Distinct CPT-induced deaths in lung cancer cells caused by clathrin-mediated internalization of CP micelles

Yu-Sheng Liu, Ru-You Cheng, Yu-Lun Lo, Chin Hsu, Su-Hwei Chen, Chien-Chih Chiu, Li-Fang Wang

Nanoscale· Volume 8· Issue 6
Publisher page

Abstract

We previously synthesized a chondroitin sulfate-graft-poly(ε-caprolactone) copolymer (H-CP) with a high content of poly(ε-caprolactone) (18.7 mol%), which self-assembled in water into a rod-like micelle to encapsulate hydrophobic camptothecin (CPT) in the core (micelle/CPT) for tumor-targeted drug delivery. As a result of the recognition of the micelle by CD44, the micelle/CPT entered CRL-5802 cells efficiently and released CPT efficaciously, resulting in higher tumor suppression than commercial CPT-11. In this study, H1299 cells were found to have a higher CD44 expression than CRL-5802 cells. However, the lower CD44-expressing CRL-5802 cells had a higher percentage of cell death and higher cellular uptake of the micelle/CPT than the higher CD44-expressing H1299 cells. Examination of the internalization pathway of the micelle/CPT in the presence of different endocytic chemical inhibitors showed that the CRL-5802 cells involved clathrin-mediated endocytosis, which was not found in the H1299 cells. Analysis of the cell cycle of the two cell lines exposed to the micelle/CPT revealed that the CRL-5802 cells arrested mainly in the S phase and the H1299 cells arrested mainly in the G2-M phase. A consistent result was also found in the evaluation of γ-H2AX expression, which was about three-fold higher in the CRL-5802 cells than in the H1299 cells. A near-infrared dye, IR780, was encapsulated into the micelle to observe the in vivo biodistribution of the micelle/IR780 in tumor-bearing mice. The CRL-5802 tumor showed a higher fluorescence intensity than the H1299 tumor at any tracing time after 1 h. Thus we tentatively concluded that CRL-5802 cells utilized the clathrin-mediated internalization pathway and arrested in the S phase on exposure to the micelle/CPT; all are possible reasons for the better therapeutic outcome in CRL-5802 cells than in H1299 cells.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Cell death mechanisms and regulation · RNA Interference and Gene Delivery · Cancer, Hypoxia, and Metabolism

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy

Kaohsiung Medical University

Kaohsiung 807, Taiwan

Department of Medicinal and Applied Chemistry

College of Life Science

Department of Physiology

Faculty of Medicine

College of Medicine

Department of Biotechnology

Institute of Medical Science and Technology

References (38)

Show source-provided references
1. Li · Biomacromolecules · 2011 · 12 · 172410.1021/bm200115v ↗
2. Ronca · Osteoarthritis Cartilage · 1998 · 6 · 1410.1016/S1063-4584(98)80006-X ↗
3. Bagari · J. Drug Targeting · 2011 · 19 · 25110.3109/1061186X.2010.492525 ↗
4. D. Naor , R. V.Sionov and D.Ish-Shalom , in Adv. Cancer Res. , ed. F. V. W. George and K. George , Academic Press , 1997 , vol. 71 , pp. 241–319
5. Kargi · Cancer Lett. · 1997 · 119 · 2710.1016/S0304-3835(97)00254-1 ↗
6. Liu · Mol. Pharm. · 2014 · 11 · 116410.1021/mp400607h ↗
7. Koo · Nanomedicine · 2005 · 1 · 7710.1016/j.nano.2004.11.002 ↗
8. Li · Curr. Med. Chem. · 2006 · 13 · 202110.2174/092986706777585004 ↗
9. Park · Biomaterials · 2005 · 26 · 105310.1016/j.biomaterials.2004.04.008 ↗
10. Pasut · Adv. Drug Delivery Rev. · 2009 · 61 · 117710.1016/j.addr.2009.02.010 ↗
11. Zhu · Biochem. Biophys. Res. Commun. · 2009 · 379 · 108410.1016/j.bbrc.2009.01.019 ↗
12. Peng · Biomaterials · 2010 · 31 · 566010.1016/j.biomaterials.2010.03.059 ↗
13. Chiu · PLoS One · 2013 · 8 · e6473910.1371/journal.pone.0064739 ↗
14. Peng · ACS Nano · 2011 · 5 · 559410.1021/nn201100m ↗
15. Sahay · J. Controlled Release · 2010 · 145 · 18210.1016/j.jconrel.2010.01.036 ↗
16. Harush-Frenkel · Biochem. Biophys. Res. Commun. · 2007 · 353 · 2610.1016/j.bbrc.2006.11.135 ↗
17. Li · Nanotechnology · 2008 · 19 · 14510210.1088/0957-4484/19/14/145102 ↗
18. Rappoport · Biochem. J. · 2008 · 412 · 41510.1042/BJ20080474 ↗
19. Smith · Int. J. Nanomed. · 2012 · 7 · 2045
20. Chen · J. Biomed. Nanotechnol. · 2015 · 11 · 95110.1166/jbn.2015.2012 ↗
21. Harush-Frenkel · Biomacromolecules · 2008 · 9 · 43510.1021/bm700535p ↗
22. Qiu · Acta Biomater. · 2014 · 10 · 202410.1016/j.actbio.2013.12.025 ↗
23. Wall · J. Am. Chem. Soc. · 1966 · 88 · 388810.1021/ja00968a057 ↗
24. Seiler · Mol. Cell. Biol. · 2007 · 27 · 580610.1128/MCB.02278-06 ↗
25. Goldwasser · Cancer Res. · 1996 · 56 · 4430
26. Fueyo · Int. J. Oncol. · 1998 · 12 · 665
27. Cliby · J. Biol. Chem. · 2002 · 277 · 159910.1074/jbc.M106287200 ↗
28. Darzynkiewicz · Ann. N. Y. Acad. Sci. · 1996 · 803 · 9310.1111/j.1749-6632.1996.tb26379.x ↗
29. Ryan · Nucleic Acids Res. · 1991 · 19 · 329510.1093/nar/19.12.3295 ↗
30. Avemann · Mol. Cell. Biol. · 1988 · 8 · 302610.1128/MCB.8.8.3026 ↗
31. Tsao · Cancer Res. · 1992 · 52 · 1823
32. Tobey · Cancer Res. · 1972 · 32 · 2720
33. Martín · Cancer Cell · 2005 · 7 · 59110.1016/j.ccr.2005.05.006 ↗
34. Zhang · Oncol. Lett. · 2013 · 6 · 38110.3892/ol.2013.1381 ↗
35. Vrhovac · Blood · 1998 · 91 · 469410.1182/blood.V91.12.4694 ↗
36. Sterlacci · J. Thoracic Oncol. · 2010 · 5 · 132510.1097/JTO.0b013e3181e77efc ↗
37. Dickey · Chromosoma · 2009 · 118 · 68310.1007/s00412-009-0234-4 ↗
38. Maeda · Adv. Drug Delivery Rev. · 2011 · 63 · 12910.1016/j.addr.2010.05.001 ↗